EUnetHTA Joint Assessment

Just as a reminder from one of our previous posts, the opportunity for open patient input in one of EUnetHTA’s joint assessment on patients using the new drug brolucizumab for treatment of neovascular age-related macular degeneration, or wet AMD, is coming to a close. The chance to contribute to this opportunity closes on July 15th, 13:00PM CEST. Follow the link below to contribute!

Newsletter Signup

To keep up to date with our news and activities,
please leave your details below

GDPR Compliance Please indicate your consent for Retina International to contact you via the email address listed for the purposes of general alerts and newsletters.